Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

294
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
294
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

538
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
538
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

306
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
306
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

771
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
771
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

334
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
334

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The performance of latent class analysis for clustering multiple long-term conditions is robust to the impact of high-prevalence conditions.

Journal of clinical epidemiology·2026
Same author

Muscle Ageing and Sarcopenia Study (MASS) Lifecourse: a valuable resource for understanding skeletal muscle ageing.

GeroScience·2026
Same author

Prioritising and ranking methodological uncertainties in the design, conduct, and analysis of trials aiming to improve health outcomes for those living with multiple long-term conditions: A protocol for a modified Delphi study.

Journal of multimorbidity and comorbidity·2026
Same author

Maintaining function and participation through tailored 24-hour movement behaviours for people living with multiple long-term conditions and frailty (The PERSONAL-AGILITY study): Protocol for a randomised controlled feasibility trial.

PloS one·2026
Same author

What barriers need to be removed to incorporate resistance exercise into the lives of older adults with long-term diabetes and prefrailty? A deductive framework analysis using the Capability, Opportunity, Motivation and Behaviour (COM-B) behavioural science model.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Using a generative co-design framework to adapt an exercise intervention as part of a multimodal intervention for patients' receiving haemodialysis with or at risk of renal cachexia.

Research involvement and engagement·2026

Related Experiment Video

Updated: Mar 7, 2026

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

1.4K

Selecting Potential Pharmacological Interventions in Sarcopenia.

Amanda J Kilsby1, Avan A Sayer2,3, Miles D Witham4

  • 1Department of Geriatric Medicine, North Tyneside General Hospital, Northumbria Healthcare Trust, Rake Lane, North Shields, NE29 8NH, UK. A.Kilsby2@newcastle.ac.uk.

Drugs & Aging
|March 2, 2017
PubMed
Summary
This summary is machine-generated.

Effective pharmacological interventions for age-related sarcopenia are needed. Research explores molecular targets and observational data to find treatments, but clinical trials require refined methods and predictive biomarkers for success.

More Related Videos

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
14:39

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

Published on: April 22, 2022

4.5K
Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

13.3K

Related Experiment Videos

Last Updated: Mar 7, 2026

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

1.4K
Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
14:39

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

Published on: April 22, 2022

4.5K
Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

13.3K

Area of Science:

  • Gerontology
  • Pharmacology
  • Muscle Biology

Background:

  • Age-related sarcopenia is a widespread and expensive condition.
  • Current pharmacological treatments for sarcopenia are limited.
  • The complex pathophysiology involves inflammation, hormonal changes, impaired regeneration, mitochondrial dysfunction, and denervation.

Purpose of the Study:

  • To review strategies for identifying and testing pharmacological interventions for sarcopenia.
  • To discuss the challenges in demonstrating efficacy in clinical trials.
  • To highlight the need for improved trial methodologies and biomarkers.

Main Methods:

  • Discusses 'bottom-up' approaches (basic science, target identification like myostatin inhibitors).
  • Explores 'top-down' approaches (observational data, e.g., ACE inhibitors and physical function).
  • Emphasizes the need for measuring both muscle mass and function in trials.

Main Results:

  • Myostatin inhibitors represent a 'bottom-up' strategy.
  • Observational data suggests potential benefits of certain medications like ACE inhibitors.
  • Clinical trials require large sample sizes and long follow-up periods.

Conclusions:

  • Developing effective pharmacological interventions for sarcopenia is crucial.
  • Improved clinical trial designs and predictive biomarkers are essential to accelerate progress.
  • Further research into sarcopenia pathophysiology and treatment is needed for the aging population.